Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures - 14/12/17
Abstract |
Background |
Previous studies examining the relationship between psoriasis (Pso), osteoporosis, and pathological fractures found conflicting results.
Objective |
To determine whether Pso and psoriatic arthritis (PsA) are associated with osteoporosis and fractures in US adults.
Methods |
Cross-sectional study of 198,102,435 children and adults, including 183,725 with Pso and 28,765 with PsA from the 2006-2012 National Emergency Department Sample, including 20% of the emergency care visits throughout the United States.
Results |
In a pooled analysis across all 7 years, patients with Pso had significantly higher odds (multivariate logistic regression; odds ratio, 95% confidence intervals) of diagnosis with osteopenia (2.86, 2.70-3.02), osteoporosis (2.97, 2.89-3.06), osteomalacia (4.40, 2.50-7.74), ankylosing spondylitis (13.34, 12.02-14.81), and pathological fractures (2.35, 2.19-2.53). Similar associations were observed for PsA. Pso was also associated with vertebral (1.17, 1.09-1.25), pelvic (1.18, 1.06-1.31), femoral (1.68, 1.60-1.78), and tibial/fibular fractures (1.28, 1.16-1.41). Whereas, PsA was associated with stress (2.87, 1.08-7.64) and vertebral (1.45, 1.24-1.70), pelvic (1.75, 1.41-2.18), femoral (2.07, 1.85-2.32), and tibial/fibular (1.60, 1.28-2.01) fractures.
Limitations |
Data on severity and treatments of Pso were not available.
Conclusion |
Pso and PsA were associated with osteopenia, osteoporosis, ankylosing spondylitis, and pathologic fractures.
Le texte complet de cet article est disponible en PDF.Key words : ankylosing spondylitis, burden, comorbidities, cost of care, emergency care, hospitalization, length of stay, osteomalacia, osteopenia, osteoporosis, psoriasis, psoriatic arthritis, urgent care
Abbreviations used : aOR, AS, BMD, CI, ED, ICD-9-CM, NEDS, PsA, Pso
Plan
| Funding sources: Supported by a grant from the Agency for Healthcare Research and Quality (K12HS023011) and the Dermatology Foundation. |
|
| Conflicts of interest: None declared. |
Vol 76 - N° 6
P. 1045 - juin 2017 Retour au numéro
Article précédent
- Answers to CME examination
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
- Brooke Rothstein, Deep Joshipura, Ami Saraiya, Rana Abdat, Huda Ashkar, Yana Turkowski, Vaneeta Sheth, Victor Huang, Shiu Chung Au, Courtney Kachuk, Nicole Dumont, Alice B. Gottlieb, David Rosmarin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?